Reviews
Section edited by Thomas F. Gajewski, MD, PhD and Per Thor Straten, PhD
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.
- REVIEW
The immune system in cancer metastasis: friend or foe?
Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...Journal for ImmunoTherapy of Cancer 2017 5:79Published on: 17 October 2017 - REVIEW
Immuno-thermal ablations – boosting the anticancer immune response
The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...Journal for ImmunoTherapy of Cancer 2017 5:78Published on: 17 October 2017 - MEETING REPORT
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...Journal for ImmunoTherapy of Cancer 2017 5:77Published on: 19 September 2017 - REVIEW
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016
Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early succe...Journal for ImmunoTherapy of Cancer 2017 5:55Published on: 18 July 2017 - REVIEW
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 ...Journal for ImmunoTherapy of Cancer 2017 5:53Published on: 18 July 2017 - REVIEW
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November...Journal for ImmunoTherapy of Cancer 2017 5:50Published on: 20 June 2017 - REVIEW
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...Journal for ImmunoTherapy of Cancer 2017 5:44Published on: 16 May 2017 - REVIEW
Systematic evaluation of immune regulation and modulation
Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...Journal for ImmunoTherapy of Cancer 2017 5:21Published on: 21 March 2017 - REVIEW
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
Chimeric antigen receptor (CAR) T-cell therapy represents a revolutionary treatment for haematological malignancies (i.e. B-ALL). However, the success of this type of treatment has not yet been achieved in sol...Journal for ImmunoTherapy of Cancer 2017 5:28Published on: 21 March 2017 - REVIEW
Combination immunotherapy: a road map
Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...Journal for ImmunoTherapy of Cancer 2017 5:16Published on: 21 February 2017 - REVIEW
Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer
Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, incl...Journal for ImmunoTherapy of Cancer 2017 5:5Published on: 17 January 2017 - REVIEW
Canine cancer immunotherapy studies: linking mouse and human
Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populatio...Journal for ImmunoTherapy of Cancer 2016 4:97Published on: 20 December 2016 - REVIEW
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succu...Journal for ImmunoTherapy of Cancer 2016 4:95Published on: 20 December 2016 - REVIEW
A New VISTA on combination therapy for negative checkpoint regulator blockade
Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-med...Journal for ImmunoTherapy of Cancer 2016 4:86Published on: 20 December 2016 - REVIEW
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple negative breast cancers (TN) are most ...Journal for ImmunoTherapy of Cancer 2016 4:59Published on: 18 October 2016 - REVIEW
Adjuvants for peptide-based cancer vaccines
Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolo...Journal for ImmunoTherapy of Cancer 2016 4:56Published on: 20 September 2016 - MEETING REPORT
What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO)
Treatment strategies that target the immune system provide the opportunity for antitumor activity across multiple cancer types, regardless of mutational status or tumor histology. While many of the initial adv...Journal for ImmunoTherapy of Cancer 2016 4:41Published on: 19 July 2016 - REVIEW
B cell regulation of the anti-tumor response and role in carcinogenesis
The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to cali...Journal for ImmunoTherapy of Cancer 2016 4:40Published on: 19 July 2016 - REVIEW
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically t...Journal for ImmunoTherapy of Cancer 2016 4:15Published on: 15 March 2016 - REVIEW
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
The incidence of pancreatic cancer has been increasing while its 5-year survival rate has not changed in decades. In the era of personalized medicine, immunotherapy has emerged as a promising treatment modalit...Journal for ImmunoTherapy of Cancer 2016 4:14Published on: 15 March 2016
.png)
No hay comentarios:
Publicar un comentario